NEW YORK – Resolution Biosciences said Monday that it has entered an agreement with Laboratory Corporation of America to commercialize its Resolution ctDx Lung test.
LabCorp plans to launch the test in the first half of 2020 and will be its exclusive provider with Resolution performing the assay as a laboratory-developed test out of its CLIA facility.
The test uses next-generation sequencing to look for actionable mutations in cell-free DNA from non-small cell lung cancer patients.
According to Kirkland, Washington-based Resolution, the assay's clinical utility has been demonstrated in several clinical studies at research centers including Memorial Sloan Kettering Cancer Center, Northern Cancer Institute of Sydney, Dana-Farber Cancer Institute, and Vanderbilt University.
"We are excited to be working with LabCorp to enable broad access to our ctDx Lung assay," Mark Li, CEO of Resolution Bioscience, said in a statement. "With our purpose-built, cell-free DNA technology platform, we look forward to making a clinically meaningful impact for a growing number of patients."
Financial and other terms of the agreement were not disclosed.